Last reviewed · How we verify

Venofer® 200 mg

American Regent, Inc. · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Venofer® 200 mg is a Small molecule drug developed by American Regent, Inc.. It is currently FDA-approved. Also known as: Iron sucrose.

Venofer 200 mg is a small molecule used to treat conditions such as hemodialysis, anemia, pregnancy complications, and chronic kidney disease stage 5. It is administered to patients undergoing hemodialysis to assess its safety and tolerability.

At a glance

Generic nameVenofer® 200 mg
Also known asIron sucrose
SponsorAmerican Regent, Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Venofer® 200 mg

What is Venofer® 200 mg?

Venofer® 200 mg is a Small molecule drug developed by American Regent, Inc..

Who makes Venofer® 200 mg?

Venofer® 200 mg is developed and marketed by American Regent, Inc. (see full American Regent, Inc. pipeline at /company/american-regent-inc).

Is Venofer® 200 mg also known as anything else?

Venofer® 200 mg is also known as Iron sucrose.

What development phase is Venofer® 200 mg in?

Venofer® 200 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing